moatshark My

All holdings

Resmed

RMD

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$75.5m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$194.88
-13.2% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-4.5%Q4 ’22
+3.8%Q1 ’23
+1.2%Q2 ’23
-32.3%Q3 ’23
-12.0%Q4 ’25
-6.8%Q1 ’26
-13.2%Q2 ’26
Q4 ’22: -4.5%; Q1 ’23: +3.8%; Q2 ’23: +1.2%; Q3 ’23: -32.3%; Q4 ’25: -12.0%; Q1 ’26: -6.8%; Q2 ’26: -13.2%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Resmed.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Resmed
Giverny Capital2.5%$75.5m$75.5mAdded +69%4 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Resmed
Bought or soldFiling
7 Oct 2026Farrell Michael J.Chairman and CEO▼ Sold4,991$226.33$1.1mForm 4
8 Sep 2026Farrell Michael J.Chairman and CEO▼ Sold4,991$222.44$1.1mForm 4
2 Sep 2026Farrell Peter CDirector▼ Sold970$234.73$228kForm 4
7 Aug 2026Farrell Michael J.Chairman and CEO▼ Sold4,991$205.69$1.0mForm 4
5 Aug 2026Farrell Peter CDirector▼ Sold8,000$225.00$1.8mForm 4

About the company

Sector
Health care · Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Financial year ends
30 June
Shares outstanding
144m at 10 Aug 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$1.6bnJun ’14
$1.8bnJun ’16
$2.3bnJun ’18
$3.0bnJun ’20
$3.6bnJun ’22
$4.7bnJun ’24
$5.7bnJun ’26
Jun ’13: $1.5bn; Jun ’14: $1.6bn; Jun ’15: $1.7bn; Jun ’16: $1.8bn; Jun ’17: $2.1bn; Jun ’18: $2.3bn; Jun ’19: $2.6bn; Jun ’20: $3.0bn; Jun ’21: $3.2bn; Jun ’22: $3.6bn; Jun ’23: $4.2bn; Jun ’24: $4.7bn; Jun ’25: $5.1bn; Jun ’26: $5.7bn
Resmed revenue and net income by year
YearRevenueNet income
Year to Jun 2026$5.7bn$1.5bn
Year to Jun 2025$5.1bn$1.4bn
Year to Jun 2024$4.7bn$1.0bn
Year to Jun 2023$4.2bn$898m
Year to Jun 2022$3.6bn$779m
Year to Jun 2021$3.2bn$475m
Year to Jun 2020$3.0bn$622m
Year to Jun 2019$2.6bn$405m
Year to Jun 2018$2.3bn$316m
Year to Jun 2017$2.1bn$342m
Year to Jun 2016$1.8bn$352m
Year to Jun 2015$1.7bn$353m
Year to Jun 2014$1.6bn$345m
Year to Jun 2013$1.5bn$307m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.